Hims & Hers Health (HIMS) said that it has begun selling Novo Nordisk (NVO) GLP-1 medicines Wegovy (semaglutide) and Ozempic (semaglutide), which are indicated for weight loss and type 2 diabetes. All ...
Zacks Investment Research on MSN
HIMS vs. DOCS: Which digital health stock offers better upside now?
Digital healthcare continues to evolve across both direct-to-consumer and professional-focused platforms, with Hims & Hers ...
Hims & Hers Health, Inc. (NYSE: HIMS) today announced that a broad assortment of Novo Nordisk’s FDA-approved GLP-1 ...
Hims & Hers is changing that reality. Through a digital-first, proactive model, life-changing care can belong to everyone, ...
The recent deal between Novo Nordisk and Hims & Hers is already resulting in new product announcements for Hims & Hers. The ...
Hims & Hers (HIMS) has taken a beating, with the stock down roughly 70% from its $70 peak and now trading below $21 per share ...
Hims & Hers Health (NYSE: HIMS) stock crashed 25% through 10:45 a.m. ET Monday morning after an eventful weekend. Where to invest $1,000 right now? Our analyst team just revealed what they believe are ...
Few people consult a doctor before attempting weight loss. Hims offers virtual weight loss support for men, including consultations and prescriptions. Hims provides GLP-1 injections, meal replacements ...
Hims & Hers Health Inc. (NYSE:HIMS) is one of the 10 Stocks Making Huge Moves Today. Hims & Hers extended its winning streak to a third consecutive day on Wednesday, jumping 10.27 percent to close at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results